Considering that ICI therapies are broadly applied in melanoma and non-small cell lung cancer (NSCLC), we retrospectively integrated pre-treatment multiomics data and immunotherapy responses from melanoma and NSCLC patients to elucidate the clinical implications of FASN mutation-mediated FA metabolism reprogramming in cancer immunotherapy. This evidence concerns the gene FASN and melanoma.